Elanco Animal Health (NYSE:ELAN) Releases FY 2026 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) issued an update on its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 1.100-1.160 for the period, compared to the consensus EPS estimate of 1.070. The company issued revenue guidance of $5.1 billion-$5.1 billion, compared to the consensus revenue estimate of $5.1 billion. Elanco Animal Health also updated its Q3 2026 guidance to 0.190-0.220 EPS.

Elanco Animal Health Stock Performance

NYSE ELAN traded up $0.74 during trading hours on Wednesday, hitting $26.34. The company’s stock had a trading volume of 9,140,258 shares, compared to its average volume of 5,368,945. The company’s 50 day simple moving average is $24.68 and its two-hundred day simple moving average is $24.09. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.16 and a quick ratio of 1.12. The company has a market cap of $13.15 billion, a P/E ratio of -52.57, a price-to-earnings-growth ratio of 1.68 and a beta of 1.67. Elanco Animal Health has a 12 month low of $13.76 and a 12 month high of $27.98.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The business had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.31 billion. During the same period in the previous year, the business earned $0.26 EPS. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, sell-side analysts expect that Elanco Animal Health will post 1.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. JPMorgan Chase & Co. upped their price objective on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Weiss Ratings upgraded shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday. TD Cowen upped their price target on shares of Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, June 18th. Wall Street Zen cut shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. Finally, Morgan Stanley increased their price target on Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Elanco Animal Health has a consensus rating of “Moderate Buy” and an average price target of $28.73.

Insiders Place Their Bets

In related news, insider Rajeev A. Modi bought 4,911 shares of Elanco Animal Health stock in a transaction dated Friday, May 15th. The shares were acquired at an average cost of $20.35 per share, with a total value of $99,938.85. Following the completion of the transaction, the insider owned 160,812 shares in the company, valued at $3,272,524.20. The trade was a 3.15% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Jeffrey N. Simmons bought 4,971 shares of the stock in a transaction on Friday, May 15th. The stock was purchased at an average price of $20.09 per share, with a total value of $99,867.39. Following the completion of the acquisition, the chief executive officer directly owned 171,971 shares in the company, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their position. The disclosure for this purchase is available in the SEC filing. 1.14% of the stock is owned by company insiders.

Key Elanco Animal Health News

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Quarterly results exceeded expectations: Elanco reported adjusted EPS of $0.34, above the $0.27 consensus and up from $0.26 a year earlier. Revenue rose 10% year over year to $1.368 billion, beating the $1.31 billion analyst estimate, while organic constant-currency growth was 8%. Elanco Animal Health Reports Second Quarter 2026 Results
• Positive Sentiment: Full-year outlook was raised: Elanco now expects 2026 adjusted EPS of $1.10 to $1.16, above the $1.07 consensus. Revenue guidance was increased to $5.09 billion-$5.14 billion, representing 6%-7% organic constant-currency growth, and adjusted EBITDA guidance was raised to $1.01 billion-$1.035 billion. Elanco Animal Health Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Innovation and balance-sheet targets improved: The company raised its 2026 innovation-revenue target to $1.25 billion and lowered its year-end net-leverage target to approximately 3.0 times adjusted EBITDA, compared with 3.1 times at the end of the second quarter. Management also projects adjusted EPS growth of approximately 20% at the midpoint of its guidance. Elanco Animal Health Reports Second Quarter 2026 Results
• Neutral Sentiment: Third-quarter guidance was broadly in line: Elanco forecast adjusted EPS of $0.19-$0.22 and revenue of approximately $1.2 billion. The EPS range begins at the analyst consensus, limiting the near-term upside surprise compared with the full-year outlook. Elanco Animal Health Q2 Key Metrics

Institutional Trading of Elanco Animal Health

Hedge funds have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Elanco Animal Health in the first quarter valued at approximately $2,065,000. Goldman Sachs Group Inc. lifted its holdings in shares of Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after purchasing an additional 2,445,872 shares during the period. Empowered Funds LLC lifted its stake in Elanco Animal Health by 35.2% during the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock valued at $166,000 after acquiring an additional 4,121 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Elanco Animal Health by 4.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock worth $18,830,000 after acquiring an additional 76,408 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in Elanco Animal Health by 2,006.9% in the second quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company’s stock valued at $4,432,000 after purchasing an additional 295,651 shares during the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.